Editor profile
Editor, Market Intelligence & Industry Briefs
Amira Al-Mansour coordinates real-time updates on MedTech funding rounds, corporate M&A, and clinical trial results. She tracks high-frequency market signals for industry leaders.
amira.al-mansour@medtechdaily.orgHow to Identify AI Washing in Medical Technology M&A? Key Difficulties in Due Diligence of Digital Health AI Assets and Analysis of New FDA Regulations, Covering CDS Guidelines, NAMs, and Clinical Trial Innovation.
This article analyzes the implementation progress of AI healthcare, enterprise strategies, market impact, regulatory challenges, and development trends over the next 3-5 years from the perspective of global medical technology industry media, helping industry readers grasp the pulse of Healthcare Innovation.
The life sciences industry is accelerating its transformation toward precision medicine and AI-driven R&D. This article analyzes the latest developments of companies such as GSK, Takeda, Vertex, Novartis, Dassault Systèmes, and BMS, exploring how strategic acquisitions, regulatory approvals, and AI infrastructure are jointly shaping the new landscape of global healthcare technology.
William Blair has recently launched research coverage on multiple biotechnology companies in quick succession and appointed a new head of biopharma investment banking, reflecting the active momentum of capital activity and innovation pipelines in the healthcare and technology sector. This article analyzes the industry trends and market implications behind this development from the perspective of industry media.
This article reviews the regulatory evolution of AI medical devices in the United States, the European Union, China, Japan, and South Korea from 2015 to 2025, and analyzes its impact on the Digital Health and Medical Devices industries.
The global digital health market is expected to reach $2.19 trillion by 2034, with a compound annual growth rate of 22.5%. The North American market leads, with telehealth and AI as the main drivers.
In 2026, the biotech and life sciences field reaches a critical turning point. AI and machine learning become R&D infrastructure, gene editing, synthetic biology, and microbiome therapies move toward clinical application, and global regulatory frameworks are being rapidly restructured. This article outlines 26 major trends, analyzing how technology, markets, capital, and policy are reshaping the healthcare innovation ecosystem.
Deep Analysis of the Ten-Year Evolution of Global AI Medical Device Regulatory Policies, Covering the United States, the European Union, China, Japan, and South Korea, Revealing Industry Challenges and Future Trends.
Medical interoperability enables healthcare professionals to instantly access patients' complete medical histories through data sharing, avoiding duplicate tests and improving diagnostic efficiency and patient experience.
Advita Ortho presented nine studies at CAOS 2026, showcasing AI-generated shoulder digital twins, automated planning, and surgical navigation for shoulder, knee, and ankle procedures.
MiniMed launches the Abbott-manufactured Instinct continuous glucose monitor in Europe, targeting over 4.5 million Abbott CGM users, aiming to drive insulin pump sales growth through sensor selection.
China's "Regulations on the Clinical Research and Translational Application of Biomedical New Technologies" (Order 818) establishes a new commercialization pathway for advanced therapies such as cell and gene therapy, allowing clinical translation and charging fees in tertiary hospitals without drug registration from the National Medical Products Administration. This signals China's intention to accelerate local innovation and standardize the drug development environment, and it is expected to become an important player in the development and manufacturing of advanced therapies.
As GLP-1 drugs evolve from injectables to oral, multi-target, and RNA therapies, the entire metabolic disease treatment market is undergoing profound changes. This article analyzes the latest industry trends, key company strategies, and development directions over the next 3-5 years.